US DOJ, FTC hear drug price reform, competition enforcement pitches
Kickbacks to pharmacy benefit managers, product-hopping, pay-for-delay agreements, patent thickets, inadequate price transparency and opaque dealings across vertically integrated conglomerates have contributed to a healthcare system rife with competition problems and...To view the full article, register now.
Already a subscriber? Click here to view full article